TrialsgrambetaRCTs are beautiful

GLP-1 receptor agonists

MACE-outcome trials of semaglutide and dulaglutide in T2DM.

  • 2019REWIND⁠Primary CV preventionIn 9,901 patients with T2DM mostly without established CV disease, dulaglutide 1.5 mg weekly reduced CV death, non-fatal MI or non-fatal stroke compared with placebo.HR 0.88Read →
  • 2016SUSTAIN-6⁠CV outcome trialIn 3,297 patients with T2DM at high CV risk, subcutaneous semaglutide 0.5 or 1.0 mg weekly reduced CV death, non-fatal MI or non-fatal stroke versus placebo.HR 0.74Read →